1 February 2018 in Complementary Therapies in Clinical Practice
3 July 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Medical misinformation can pose serious threats to public health. This commentary explores the pharmacist's unique role in addressing and mitigating the impact of medical misinformation. Pharmacists are uniquely positioned to engage with other healthcare providers, patients, and communities to dispel myths, provide accurate information, and promote evidence‐based healthcare decision‐making. This commentary showcases examples of the multifaceted roles of pharmacists in combating medical misinformation. It explores various strategies and interventions that can be used by pharmacists, including patient education, effective communication, information dissemination, and community engagement. Pharmacists' interventions are often at the intersection of medication management and health information needs, making them integral in ensuring patients and providers make informed healthcare choices. Moreover, this commentary highlights the impact pharmacists can have as advocates for scientific rigor and evidence‐based practices within healthcare systems to educate against medical misinformation and discusses the need for continued education, training, and support for pharmacists to excel in their roles as healthcare educators and medication experts. Pharmacists have a role in countering medical misinformation when serving patients by providing information that empowers a more informed society.
14 January 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Introduction: Single maintenance and reliever therapy (SMART) with a combination inhaled corticosteroid‐formoterol inhaler is the preferred asthma treatment by the Global Initiative for Asthma and the National Asthma Education and Prevention Program guidelines. These recommendations have been slow to be implemented routinely into clinical practice.Methods: This was an observational cohort study conducted in a family medicine residency program clinic. A clinical pharmacist‐led initiative to implement SMART, which included provider education and the development of clinical tools to facilitate SMART prescribing, was assessed. Year 1 (Y1; pre‐intervention) and year 2 (Y2; post‐intervention) were compared.Outcomes: The primary outcome was to evaluate the impact of this initiative on the frequency of SMART (budesonide‐formoterol without albuterol) prescribing. Prescription frequencies for albuterol and budesonide‐formoterol were also compared separately. Secondary outcomes were Asthma Control Test (ACT) scores and prescribing frequencies among faculty and resident physicians.Results: The total number of eligible patients in the clinic population was 807, and 459 of these patients met the inclusion criteria. There were more females than males, and the mean age was 39. About 24% had a language preference other than English and 22% required an interpreter. The percentage of patients who were prescribed SMART significantly increased from 0.44% to 11.5% (p < 0.001). Budesonide‐formoterol prescriptions increased from 7.4% to 34.6% (p < 0.001). Albuterol metered‐dose inhaler prescriptions decreased from 79.7% to 66.2% (p < 0.001). Prescribing patterns were similar for patients of faculty physicians (n = 258) and resident physicians (n = 196). Only 164 (35.7%) patients had an ACT score in Y1 and Y2, and the mean ACT score was not significantly different between Y1 and Y2 (p = 0.973).Conclusion: A clinical pharmacist‐led SMART asthma prescribing initiative was associated with a significant increase in SMART prescribing, a significant increase in budesonide‐formoterol prescribing, and a significant decrease in albuterol prescribing.
11 September 2026 in Kidney Medicine